Search Results
Your search for The ASCO matches 21112 pages
Showing 13301 - 13350Gut Bacteria May Enhance, or Hamper, Response to Anti–PD-1 Agents
The microbiome has become an area of intense interest for many health-related reasons. Add to this list the potential for a positive or a negative effect on responsiveness to immunotherapy. Gut microbiota that were more diverse, and that contained an abundance of a particular bacterial species,...
‘Non-Engineered’ T-Cell Therapy Produces Durable Responses in Hematologic Malignancies
Adoptive T-cell therapy using “non-engineered” T cells has been showing activity in hematologic malignancies, according to a presentation by Ann M. Leen, PhD, at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.1 Dr. Leen is an immunologist and works at the Center for Cell and Gene Therapy,...
ASCO’s State of Cancer Care in America: 2017 Report Acknowledges Both the Progress Made in Oncology Care and the Challenges Ahead
Despite advances in cancer risk assessment, prevention, disease detection, drug development, and health-care delivery, which have led to unparalleled reductions in cancer incidence and mortality, access to affordable health care and increased administrative burdens placed on oncology practices...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer
Maintenance therapy with the tablet formulation of olaparib (Lynparza) significantly prolonged progression-free survival in patients with platinum-sensitive relapsed ovarian cancer and mutations in BRCA1/2 in the phase III SOLO2 trial, presented at the 2017 Society of Gynecologic Oncology (SGO)...
AACR 2017: Patients With Triple-Negative Breast Cancer Who Responded to Atezolizumab Had Long-Term Survival Benefit
Among patients with metastatic triple-negative breast cancer who were treated with the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq), those who responded to the treatment had a longer overall survival compared with those who did not respond, according to data...
AACR 2017: Combination of Nivolumab and Ipilimumab Improved Overall Survival in Advanced Melanoma
Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab, and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to...
AACR 2017: 5-Year Survival Rate for Nivolumab-Treated Advanced Lung Cancer Higher Than Historical Rate in Early-Phase Trial
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non–small cell lung cancer (NSCLC), with a 5-year survival rate of 16%, according to data from a phase I clinical trial presented by Brahmer et al at the American...
Palbociclib Receives FDA Approval and Expanded Indication for First-Line Metastatic Breast Cancer
On March 31, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for a first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (Ibrance), based on the results from the confirmatory phase III trial PALOMA-2. The FDA action converts the...
AACR 2017: Combination HER2-Targeted Therapy Effective in Heavily Pretreated HER2-Positive Colorectal Cancer
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results from the phase II HERACLES clinical trial, presented by Siena et al at the ...
AACR 2017: Addition of TTFields to Temozolomide Treatment Improves Survival for Patients With Glioblastoma
Patients with glioblastoma who wore a medical device that delivers alternating electrical fields in addition to being treated with the chemotherapeutic temozolomide had significantly improved median overall survival compared with those treated with temozolomide only, according to final results from ...
AACR 2017: Cancer Type and Mutation Identity Influenced Response to Neratinib in a Basket Clinical Trial
In the phase II SUMMIT clinical trial, the likelihood that a patient’s cancer responded to the investigational pan-HER–targeted therapeutic neratinib was influenced by both the cancer type and the identity of the gene mutation present in the cancer, according to results presented by...
Racial and Ethnic Disparities in Gene-Expression Profiling Tests in Breast Cancer
For a proportion of patients, including women with hormone receptor–positive breast cancer, gene-expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options. Gene-expression...
New NCCN Radiation Therapy Compendium Aids in Decision-Making for Patients With Cancer
Radiation therapy, either alone or in combination with chemotherapy or surgery, is one of the most common treatment options for people with cancer. Nearly two-thirds of patients with cancer in the United States receive radiation therapy during their illness. To support clinical decision-making...
FDA Grants Osimertinib Full Approval in Metastatic EGFR T790M Mutation–Positive NSCLC
On March 30, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to osimertinib (Tagrisso) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer (NSCLC), as detected by an...
First-in-Human Clinical Trial of ONC201 in Patients With Refractory Solid Tumors
A first-in-human clinical trial examining the investigational small-molecule drug ONC201 in patients with advanced solid tumors showed the oral agent to be well tolerated at the recommended phase II dose, according to Rutgers Cancer Institute of New Jersey investigators whose research also showed...
Significant Increase in Number of Women Tested for BRCA Gene, but Many High-Risk Patients Remain Unidentified
About 5% to 10% of breast cancer cases and 10% to 18% of ovarian cancer cases can be attributed to two BRCA genetic mutations. Testing for these genetic abnormalities has risen steadily over the past decade. Previously, mainly women with a history of cancer were referred for genetic testing, but as ...
Palliative Care Consultations for Patients With Advanced Cancers May Reduce Hospitalization and Improve Quality of Care
Patients admitted to the hospital with advanced cancers who were referred early to palliative care had decreased health-care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai. Published...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups and specifies the most effective...
New Study Finds Most Cancer Mutations Due to Random DNA-Copying Errors
Johns Hopkins Kimmel Cancer Center scientists report data from a new study providing evidence that random, unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer. Their research is grounded on a novel mathematic model based on DNA...
Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment
Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the evidence for using neoadjuvant and adjuvant systemic therapies in resectable and borderline resectable pancreatic cancer.
Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses selecting first- and second-line therapies for patients with advanced bladder cancer and the emerging data and role of immune checkpoint inhibitors.
Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies
Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.
Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer
Paul M. Cinciripini, PhD, of The University of Texas MD Anderson Cancer Center, discusses the oncologist’s role in addressing and documenting cancer patients’ smoking and cessation attempts as well as treatment advances.
David G. Pfister, MD, on HPV and Head and Neck Cancer
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the link between human papillomavirus and oropharyngeal cancers and what is known about the effect of HPV on treatment response and outcome.
Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer
Christina S. Chu, MD, of Fox Chase Cancer Center, discusses the link between human papillomavirus and genital cancers and what is known about the effect of HPV on treatment response and outcome.
Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development
Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...
Conquer Cancer Foundation Conquerors Circle Donors
The Conquerors Circle is the Conquer Cancer Foundation’s first-ever donor appreciation society. Donors who contribute $1,000 annually are members of the Conquerors Circle. In appreciation for their generous and loyal support of the Conquer Cancer Foundation, Conquerors Circle members receive...
An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support
On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...
New ASCO Answers Fact Sheets on MDS, Bone Marrow Transplant for Your Practice
Be sure to check out new ASCO Answers fact sheets on myelodysplastic syndrome (MDS) and understanding bone marrow transplantation at Cancer.Net. These 1-page (front and back) introductions include an overview, illustrations, terms to know, and questions to ask the doctor. Find these and a library...
ASCO Research Community Forum Offers Tools, Resources to Support Cancer Research Sites
As part of ASCO’s efforts to support cancer researchers and research sites, the ASCO Research Community Forum was created in 2010 to help physician investigators and research staff overcome common barriers to conducting research and enhance their research-site operations. The Forum is a go-to...
ASCO Launches Its New Journal Dedicated to Informatics
On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...
New Supportive Care Resources From NCCN Help Patients With Cancer Confront Distress
All patients with cancer experience some level of distress associated with their cancer diagnosis and the effects of the disease and its treatment—regardless of the stage of disease. Not only does distress affect a patient’s mental and psychosocial well-being, but because distress is a...
Major Pharmaceutical Companies Collaborate in NCCN Research Project
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim and Eli Lilly are collaborating with NCCN to study combination therapeutic agents in ...
SIOG 2017 Advanced Course in Treviso, Italy
The International Society of Geriatric Oncology (SIOG) has a workshop to educate young investigators in geriatric oncology research. The SIOG Advanced Course, which is held in Treviso, Italy (June 28–July 1, 2017), is our unique continuing medical education–accredited training program led by...
Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126
Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment 126
Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a programmed cell...
Financial Burden of Targeted Oral Therapy for Patients With Chronic Myeloid Leukemia
In a study reported in the Journal of Oncology Practice, Chan Shen, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the...
Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy
In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...
Intermittent Sunitinib in Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Moshe C. Ornstein, MD, of Cleveland Clinic Taussig Cancer Institute, and colleagues found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. In...
Potential Surrogate for All-Cause Mortality Risk in Localized Prostate Cancer
In a study reported in JAMA Oncology, Trevor J. Royce, MD, of Harvard Radiation Oncology Program, Brigham and Women’s Hospital, and colleagues found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and...
Reducing Debilitating Symptoms of Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Tamas Hickish, MD, of Poole Hospital NHS Foundation Trust, Dorset, England, and colleagues found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite ...
Fox Chase Junior Investigators Win Awards for Pilot Projects
Fox Chase Cancer Center is pleased to announce the results of its American Cancer Society Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase and Temple University Hospital. The awardees are Yibin Yang, ...
Examining the Impact of ‘Death With Dignity’ Legislation
Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...
Discrimination in Medical Education—Another Perspective
I read with great interest Dr. Robert E. Montenegro’s comments in the The ASCO Post, January 25, 2017, where he felt “marginalized” when questioned about his country of origin or the quality of his English. As physicians, we constantly deal in a world of uncertainties and are required to address...
Arti Hurria, MD, Named Vice Provost at City of Hope
Geriatrician-oncologist Arti Hurria, MD, has been named Vice Provost for Clinical Faculty at City of Hope. “I spent most of my formative years at City of Hope and was very fortunate,” said Dr. Hurria, who’s been at the medical center for 10 years. “I had mentors who helped me along the way and...
Chief Clinical Officer’s Distinguished Chair Created at City of Hope to Honor Alexandra M. Levine, MD, MACP
A significant philanthropic gift from the Campbell family of Las Vegas, Nevada, will establish a new endowed Chair to honor City of Hope’s former Chief Medical Officer Alexandra M. Levine, MD, MACP. The recipient of the Deana and Steve Campbell Chief Clinical Officer’s Distinguished Chair, to be...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
